Pharmafile Logo

Oncology innovation: The human cost of keeping pace with advances in cancer care

November 18, 2026 |  

New research from Inizio Evoke explores the growing complexity of oncology innovation and how pharmaceutical companies can better support healthcare professionals (HCPs).

- PMLiVE

The pace of oncology innovation is transforming cancer care. From breakthrough therapies to advances in precision medicine, scientific progress is creating new opportunities for patients. Yet translating these advances into clinical practice is becoming increasingly complex. 

A new white paper, authored by Maria Dzialo, PhD, Associate Director, Medical Strategy, Inizio Evoke, Chasing the Fourth Wave: The human cost of keeping pace, explores the hidden pressures facing oncologists, drawing on research conducted across six countries. 

Read the white paper here. 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Oncology innovation: The human cost of keeping pace with advances in cancer care

New research from Inizio Evoke explores the growing complexity of oncology innovation and how pharmaceutical companies can better support healthcare professionals (HCPs).

AI-enabled biotech commercialization for a successful US therapy launch with Tonix

Inizio helped Tonix successfully launch the first FDA-approved therapy in its class in almost two decades by delivering an integrated, AI-enabled commercialization program spanning analytics, field operations, and launch readiness.

How pharma companies can use AI to scale personalized engagement without increasing complexity

AI is creating a world of opportunities for pharma companies to deliver more personalized HCP and patient engagement. But realizing the full potential of AI takes more than just introducing…

Creating the conditions for product launch success in a time of volatility

Volatility is reshaping the conditions for successful product launches. Market dynamics can shift quickly, assumptions can change, and teams are increasingly expected to make confident decisions in response.

Navigating uncertainty in life sciences

The life sciences industry is changing fast. Advances in AI, increasingly complex science, shifting market dynamics and evolving patient needs are creating new challenges for organizations developing and commercializing treatments….

Inizio appoints Oisín Ó Gógáin as Chief People Officer

Inizio has appointed Oisín Ó Gógáin as Chief People Officer.

Pharma leadership strategies for talent, AI adoption, and continuous learning

In a recent interview with Pharma Exec, Elaine Ferguson, Global President of Inizio Medical, explores how pharma leadership can support talent development, use AI to augment the workforce, encourage continuous…

Smarter science, sharper strategy: Expert insights from ASCO® 2026

As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?

Intelligent Commercialization™ across the pharma lifecycle

Pharma teams are under growing pressure to navigate launch complexity, identify risks earlier, and engage HCPs more effectively.

Four steps to a smarter congress strategy: A practical guidebook

This guidebook explores how Intelligent Congress helps pharma teams create more coordinated, measurable, and impactful congress strategies.